News

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® ...
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
While Gilead Sciences' HIV prevention drug lenacapavir got approved by the US Food and Drug Administration (FDA), its made- ...
Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be ...